We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LOTZ
11326
CALL
DELISTED
CarLotz, Inc. Class A Common Stock
LOTZ
$99K ﹤0.01%
252,200
-52,900
-17% -$39.2K
CPSH icon
11327
CPS Technologies
CPSH
$83.6M
$98K ﹤0.01%
32,547
+11,350
+54% +$42.1K
NG icon
11328
CALL
NovaGold Resources
NG
$3.48B
$98K ﹤0.01%
20,400
-22,200
-52% -$139K
PYPD icon
11329
PUT
PolyPid
PYPD
$90.9M
$98K ﹤0.01%
707
-43
-6% -$6.43K
VTGN icon
11330
PUT
VistaGen Therapeutics
VTGN
$11.9M
$98K ﹤0.01%
3,727
+2,714
+268% +$95.8K
NETI
11331
PUT
DELISTED
Eneti Inc.
NETI
$98K ﹤0.01%
16,000
+800
+5% +$5.13K
KLR
11332
PUT
DELISTED
Kaleyra, Inc.
KLR
$98K ﹤0.01%
13,686
+7,486
+121% +$110K
QUOT
11333
PUT
DELISTED
Quotient Technology Inc
QUOT
$98K ﹤0.01%
32,900
-1,200
-4% -$5.69K
BDTX icon
11334
CALL
Black Diamond Therapeutics
BDTX
$116M
$97K ﹤0.01%
+39,400
New +$91.6K
BDTX icon
11335
PUT
Black Diamond Therapeutics
BDTX
$116M
$97K ﹤0.01%
39,600
+18,200
+85% +$42.3K
MIR icon
11336
PUT
Mirion Technologies
MIR
$3.96B
$97K ﹤0.01%
16,900
-40,900
-71% -$301K
NNY icon
11337
Nuveen New York Municipal Value Fund
NNY
$157M
$97K ﹤0.01%
+11,397
New +$99.2K
PLSE icon
11338
Pulse Biosciences
PLSE
$3.18B
$97K ﹤0.01%
+63,401
New +$159K
SCYX icon
11339
CALL
SCYNEXIS
SCYX
$51.5M
$97K ﹤0.01%
6,500
+3,900
+150% +$75.1K
FMTX
11340
PUT
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$97K ﹤0.01%
14,100
-3,900
-22% -$27.4K
MACK
11341
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$97K ﹤0.01%
+16,211
New +$91.5K
ALDX icon
11342
PUT
Aldeyra Therapeutics
ALDX
$94.1M
$96K ﹤0.01%
24,100
-33,000
-58% -$113K
BGC icon
11343
PUT
BGC Group
BGC
$5.33B
$96K ﹤0.01%
28,400
-227,700
-89% -$793K
HLIT icon
11344
CALL
Harmonic Inc
HLIT
$1.52B
$96K ﹤0.01%
+11,100
New +$99.9K
JRS icon
11345
Nuveen Real Estate Income Fund
JRS
$246M
$96K ﹤0.01%
+10,170
New +$107K
PWP icon
11346
CALL
Perella Weinberg Partners
PWP
$1.29B
$96K ﹤0.01%
16,400
-100
-0.6% -$723
PWP icon
11347
PUT
Perella Weinberg Partners
PWP
$1.29B
$96K ﹤0.01%
16,400
-9,900
-38% -$71.6K
SRAD icon
11348
PUT
Sportradar
SRAD
$4.09B
$96K ﹤0.01%
+12,200
New +$133K
TERN
11349
DELISTED
Terns Pharmaceuticals
TERN
$96K ﹤0.01%
+38,810
New +$77.5K
WEBL icon
11350
CALL
Direxion Daily Dow Jones Internet Bull 3X ETF
WEBL
$109M
$96K ﹤0.01%
+11,800
New +$186K

Similar funds

Ken Griffin's Q2 2022 Portfolio in Review

As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.